{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Altreno&page=5",
    "query": {
      "intervention": "Altreno",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 185,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Altreno&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Altreno&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T10:58:34.576Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00001504",
      "title": "A Phase I Trial of Tamoxifen and 9-Cis-Retinoic Acid in Breast Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Breast Neoplasm"
      ],
      "interventions": [
        {
          "name": "9-cis-Retinoic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 18,
      "start_date": "1996-05",
      "completion_date": "2002-01",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001504"
    },
    {
      "nct_id": "NCT03442985",
      "title": "An Efficacy and Safety Study of Palovarotene for the Treatment of MO",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Exostoses, Multiple Hereditary"
      ],
      "interventions": [
        {
          "name": "Palovarotene 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Palovarotene 5.0 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Clementia Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "2 Years to 14 Years"
      },
      "enrollment_count": 193,
      "start_date": "2018-03-22",
      "completion_date": "2020-10-30",
      "has_results": true,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Sacramento, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "West Palm Beach",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03442985"
    },
    {
      "nct_id": "NCT00001509",
      "title": "A Phase II Trial of All-Trans-Retinoic Acid in Combination With Interferon-Alpha 2a in Children With Recurrent Neuroblastoma or Wilms' Tumor",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nephroblastoma",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "IFN-alpha with retinoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 60,
      "start_date": "1996-07",
      "completion_date": "2000-05",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001509"
    },
    {
      "nct_id": "NCT00006239",
      "title": "Phenylbutyrate and Tretinoin in Treating Patients With Hematologic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Diseases"
      ],
      "interventions": [
        {
          "name": "sodium phenylbutyrate",
          "type": "DRUG"
        },
        {
          "name": "tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2000-12",
      "completion_date": "2005-03",
      "has_results": false,
      "last_update_posted_date": "2017-09-29",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006239"
    },
    {
      "nct_id": "NCT05345002",
      "title": "All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma",
        "IDH Mutation",
        "Astrocytoma",
        "Oligodendroglioma"
      ],
      "interventions": [
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        },
        {
          "name": "All-trans retinoic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stephen Bagley, MD, MSCE",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2022-11-16",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-02-20",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05345002"
    },
    {
      "nct_id": "NCT01048086",
      "title": "90Y DOTA/Retinoic Acid for Neuroblastoma and Neuroendocrine Tumor (NET)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuroblastoma",
        "Neuroendocrine Tumor"
      ],
      "interventions": [
        {
          "name": "Retinoic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "6 Months to 30 Years"
      },
      "enrollment_count": 0,
      "start_date": "2009-06",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2016-06-21",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Iowa City, Iowa",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01048086"
    },
    {
      "nct_id": "NCT00969722",
      "title": "A Study of MAb-3F8 Plus Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Versus 13-cis-Retinoic Acid (RA) Plus GM-CSF in Primary Refractory Neuroblastoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Primary Refractory Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "MAb-3F8",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "13-cis-Retinoic Acid",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "United Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Months",
        "maximum_age": "13 Years",
        "sex": "ALL",
        "summary": "18 Months to 13 Years"
      },
      "enrollment_count": 1,
      "start_date": "2009-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-03-08",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00969722"
    },
    {
      "nct_id": "NCT00647556",
      "title": "Adapalene Gel 0.3% Versus Tretinoin 0.05% Emollient Cream for Treatment of Photodamage",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Photoaging"
      ],
      "interventions": [
        {
          "name": "adapalene gel, 0.3%",
          "type": "DRUG"
        },
        {
          "name": "tretinoin 0.05% emollient cream",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2008-04",
      "completion_date": "2010-01",
      "has_results": true,
      "last_update_posted_date": "2022-08-01",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00647556"
    },
    {
      "nct_id": "NCT00003598",
      "title": "UMCC 9609 Tretinoin in Preventing Cancer of the Cervix in Patients With Cervical Neoplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cervical Cancer",
        "Precancerous/Nonmalignant Condition"
      ],
      "interventions": [
        {
          "name": "tretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Michigan Rogel Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "14 Years and older · Female only"
      },
      "enrollment_count": 180,
      "start_date": "1999-01",
      "completion_date": "2009-11",
      "has_results": false,
      "last_update_posted_date": "2010-09-22",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00003598"
    },
    {
      "nct_id": "NCT01125930",
      "title": "Atralin Gel for the Treatment of Rosacea",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "vehicle gel",
          "type": "DRUG"
        },
        {
          "name": "Atralin gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lisa E. Maier",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 68,
      "start_date": "2010-05",
      "completion_date": "2013-01",
      "has_results": true,
      "last_update_posted_date": "2014-07-16",
      "last_synced_at": "2026-10-21T10:58:34.576Z",
      "location_count": 1,
      "location_summary": "Ann Arbor, Michigan",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01125930"
    }
  ]
}